COMMENTARY

Thorny Path Ahead toward Trial Rollout of Cost-Effective Assessment in FY2016; Chuikyo to Begin Discussions on May 27

May 26, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Sovaldi (sofosbuvir) may have received even a higher NHI price if its cost-effectiveness had been assessed - some officials at the Ministry of Health, Labor and Welfare (MLHW) and the Central Social Insurance Medical Council (Chuikyo) said. Gilead Sciences K.K.’s…

To read the full story

HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
January 6, 2026
Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise
December 22, 2025
FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed
December 9, 2025
MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…